Concepedia

Extravascular Bioavailability

Extravascular Bioavailability is the fraction of an administered non-intravenous drug dose that reaches the systemic circulation in its intact form, relative to a reference intravenous dose, accounting for incomplete absorption and presystemic metabolism.

56

Publications

2.7K

Citations

192

Authors

74

Institutions

Publications per year

2017–2026

1

Parents

Publications

56

Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution

Agnès Girard, D Girard, A. R. English et al. · Antimicrobial Agents and Chemotherapy · 1987 · 323 citations

, , +14

Bioavailability of dexmedetomidine after extravascular doses in healthy subjects

Markku Anttila, Jani Penttilä, Antti Helminen et al. · British Journal of Clinical Pharmacology · 2003 · 301 citations · Full text

, , +16

The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction

Petra Laeis, Kurt Püchler, Wilhelm Kirch · Journal of Hypertension · 2001 · 156 citations

, , +15

Effect of glycosylation on the in vivo circulating half-life of ribonuclease.

John Baynes, Finn Wold · Journal of Biological Chemistry · 1976 · 151 citations · Full text

, , +15

Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration

Siddig İbrahim Abdelwahab, Manal Mohamed Elhassan Taha, Sheikh . et al. · International Journal of Nanomedicine · 2013 · 124 citations · Full text

, , +17

1–5 of 56

Authors

192

  1. DN
    Dale N. Gerding

    Edward Hines, Jr. VA Hospital, United States

    4 publications · 64 citations

    4

    h-index

  2. LR
    Lance R. Peterson

    Northwestern University, United States

    4 publications · 64 citations

    4

    h-index

  3. LL
    L L Van Etta

    Duluth Clinic, United States

    3 publications · 46 citations

    3

    h-index

  4. AG
    Agnès Girard

    Pfizer (United States), United States

    2 publications · 396 citations

    2

    h-index

  5. DG
    D Girard

    Pfizer (United States), United States

    2 publications · 396 citations

    2

    h-index

1–5 of 192

Institutions

74

  1. Bispebjerg Hospital

    Copenhagen, Denmark

    3 h-index

    9 publications

    433 citations

  2. Cancer Society of New Zealand

    Wellington, New Zealand

    2 h-index

    12 publications

    687 citations

  3. Pfizer (United States)

    New York, United States

    2 h-index

    11 publications

    2.8K citations

  4. Universiti Putra Malaysia

    Seri Kembangan, Malaysia

    2 h-index

    4 publications

    394 citations

  5. University of Auckland

    Auckland, New Zealand

    2 h-index

    12 publications

    687 citations

  6. Boston Children's Hospital

    Boston, United States

    1 h-index

    1 publications

    27 citations

  7. South China Agricultural University

    Guangzhou, China

    1 h-index

    2 publications

    26 citations

  8. Frederiksberg Hospital

    Frederiksberg, Denmark

    1 h-index

    2 publications

    164 citations

1–8 of 74

Venues

  1. Antimicrobial Agents and Chemotherapy

    AAC · 5 publications · 393 citations

    5

    h-index

  2. PubMed

    Repository · 5 publications · 119 citations

    5

    h-index

  3. 3

    h-index

  4. Thrombosis and Haemostasis

    1 publications · 26 citations

    2

    h-index

  5. Acta Physiologica Scandinavica

    APS · 2 publications · 50 citations

    2

    h-index

1–5